CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 4.0

ph-index = 11

Forward Citations = 564(Granted Patents)

Location History:

Tokyo, JP (1983 - 2013)
Minato-ku, JP (2011 - 2015)

Company Filing History:

25 out of 210

Kabushiki Kaisha Yakult Honsha

patents

1 out of 2,313

Terumo Kabushiki Kaisha

patents

1 out of 200

Daiichi Pharmaceutical Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 1983-2015

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9174979 - Phenanthroindolizidine compound and NFκB inhibitor containing same as active ingredient (2015-11-03),

2. 8569327 - Phenanthroindolizidine derivative and NFκB inhibitor containing same as active ingredient (2013-10-29),

3. 8501813 - γ-secretase inhibitor (2013-08-06),

4. 8476438 - Process for production of camptothecin derivative (2013-07-02),

5. 8466287 - Process for producing tricyclic ketone (2013-06-18),

6. 8067595 - Process for producing tricyclic ketone (2011-11-29),

7. 7897772 - Acid addition salt of irinotecan (2011-03-01),

8. 7846473 - Irinotecan preparation (2010-12-07),

9. 7488825 - Method for preparing polymorphism of irinotecan hydrochloride (2009-02-10),

10. 7378555 - Method of synthesizing camptothecin-relating compounds (2008-05-27),

11. 7126000 - Method of synthesizing camptothecin-relating compounds (2006-10-24),

12. 6743918 - Process for producing camptothecin (2004-06-01),

13. 6310210 - Camptothecin derivatives (2001-10-30),

14. 6268381 - Taxane derivatives (2001-07-31),

15. 6136808 - Taxane derivatives (2000-10-24),

Title: Seigo Sawada: A Pioneer in NFκB Inhibitory Compounds

Introduction: Seigo Sawada, based in Tokyo, Japan, is a distinguished inventor known for his contributions in the field of pharmacology and biochemistry. With a remarkable portfolio of 25 patents, he has dedicated his career to developing innovative compounds that address critical health issues.

Latest Patents: Among his latest patents, Sawada has introduced the Phenanthroindolizidine compound and an NFκB inhibitor containing the same as an active ingredient. This novel compound showcases an excellent inhibitory effect against NFκB, specifically detailed within his patent documents. The complex structure includes various groups, such as lower alkyl groups and hydroxyl groups, demonstrating the intricate chemical knowledge required for such innovative discoveries.

Career Highlights: Sawada has held significant positions in well-regarded companies, including Yakult Honsha Co., Ltd. and Terumo Corporation. His work in these esteemed organizations has been instrumental in advancing research and innovations in medical compounds.

Collaborations: Throughout his career, Sawada has collaborated with prominent colleagues, such as Takashi Yaegashi and Tadashi Miyasaka. Their joint efforts have fostered an environment of innovation and excellence, contributing to the success of their projects.

Conclusion: Seigo Sawada's extensive experience and numerous patents highlight his pivotal role as an innovator in the field of NFκB inhibitory compounds. His ongoing contributions to pharmacology continue to inspire future advancements in medical research and development.

This text is generated by artificial intelligence and may not be accurate.